文献速递产科母胎医学

围产期阿片类药物使用障碍:整合与非整合治疗回顾性队列研究

Integrated vs nonintegrated treatment for perinatal opioid use disorder: retrospective cohort study.
PubMed 文献 · Am J Obstet Gynecol MFM · 2021-09-17

该回顾性队列研究纳入2015-2017年农村学术医疗中心分娩的阿片类药物使用障碍孕妇225例,比较整合治疗(92例)与非整合治疗(133例)的围产结局。整合治疗与早产风险降低、分娩时母亲尿毒理学阳性率降低及婴儿住院时间缩短相关,且该关联由产科就诊次数介导。

要点

  • 整合治疗组早产率11.8%显著低于非整合组26.6%(P<.001)
  • 整合治疗组婴儿住院时间6.5±4.8天,短于非整合组10.7±16.2天
  • 整合治疗组分娩时母亲尿毒理学阳性率35.9%,低于非整合组74.4%(P<.001)

核心结论

  • 在农村阿片类药物使用障碍孕妇中,整合产科与成瘾治疗与早产风险降低、分娩时母亲尿毒理学阳性风险降低及婴儿住院时间缩短相关。
  • 该关联由孕期产科就诊次数介导,提示通过服务整合增加产科参与可能改善围产结局。

研究设计与样本

  • 观察性回顾性队列研究,纳入2015至2017年农村学术医疗中心分娩的阿片类药物使用障碍孕妇225例。
  • 整合治疗组92例,非整合治疗组133例。
  • 采用逆概率加权回归模型调整协变量失衡,评估治疗模式对早产及胎粪或脐带毒理学阳性风险的影响。
  • 使用准贝叶斯蒙特卡洛算法探索产科就诊次数是否介导该关系。

主要发现

  • 整合治疗组早产率11.8%,非整合组26.6%(P<.001)。
  • 整合治疗组婴儿住院时间6.5±4.8天,非整合组10.7±16.2天。
  • 稳健逆概率加权模型显示,整合治疗与早产预测概率降低74.7%相关(平均处理效应-0.19;标准误0.14;P<.001)。
  • 胎粪或脐带毒理学阳性率两组无差异(29.4% vs 34.6%;P=.41)。
  • 整合治疗组分娩时母亲尿毒理学阳性率显著低于非整合组(35.9% vs 74.4%;P<.001)。

关键数值与推荐

  • 整合治疗组早产率11.8%,非整合组26.6%(P<.001)。
  • 整合治疗组婴儿住院时间6.5±4.8天,非整合组10.7±16.2天。
  • 整合治疗与早产预测概率降低74.7%相关(平均处理效应-0.19;标准误0.14;P<.001)。
  • 胎粪或脐带毒理学阳性率:整合组29.4%,非整合组34.6%(P=.41)。
  • 分娩时母亲尿毒理学阳性率:整合组35.9%,非整合组74.4%(P<.001)。

临床怎么用

  • 对阿片类药物使用障碍孕妇,可考虑将成瘾治疗与产科保健整合于同一协调服务中。
  • 整合服务可能通过增加产科就诊参与度来降低早产风险并缩短婴儿住院时间。
  • 整合治疗未显著降低胎粪或脐带毒理学阳性率,提示第二、三孕期物质使用监测仍需关注。

局限性

  • 本研究为观察性回顾性队列,存在残余混杂可能。
  • 研究对象来自单一农村学术医疗中心,外推性受限。
  • 样本量有限(n=225),部分亚组分析效能可能不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pregnant women with opioid use disorder and their infants often experience worse perinatal outcomes than women without opioid use disorder, including longer hospitalizations after delivery and a higher risk for preterm delivery. Integrated treatment models, which combine addiction treatment and maternity care, represent an innovative approach that is widely endorsed, however, limited studies have compared the outcomes between integrated and standard, nonintegrated programs from real-world programs. OBJECTIVE: This study aimed to evaluate the perinatal and substance use outcomes for pregnant women with opioid use disorder receiving coordinated, colocated obstetrical care and opioid use disorder treatment (integrated treatment) and to compare it with those of women receiving obstetrical care and opioid use disorder treatment in distinct programs of care (nonintegrated treatment). STUDY DESIGN: In this observational, retrospective cohort study, we abstracted the perinatal and opioid use disorder treatment data from the records of pregnant women with opioid use disorder (n=225) who delivered at a rural, academic medical center from 2015 to 2017. The women either received integrated (n=92) or nonintegrated (n=133) opioid use disorder treatment and obstetrical care. Using inverse probability weighted regression models to adjust for a potential covariate imbalance, we evaluated the impact of the treatment model on the risk for preterm delivery and positive meconium or umbilical cord toxicology screens. We explored whether the number of obstetrical visits mediated this relationship by using a quasi-Bayesian Monte Carlo algorithm. RESULTS: Women receiving integrated treatment were less likely to deliver prematurely (11.8% vs 26.6%; P<.001) and their infants had shorter hospitalizations (6.5±4.8 vs 10.7±16.2 days). Using a robust inverse probability weighted model showed that receiving integrated treatment was associated with a 74.7% decrease in the predicted probability of preterm delivery (average treatment effect, -0.19; standard error, 0.14; P<.001). There were no differences in the risk for a positive meconium or umbilical cord toxicology screen, a marker for second and third trimester substance use, between women receiving integrated treatment and those receiving coordinated treatment (29.4% vs 34.6%; P=.41), however, integrated treatment was associated with significantly lower rates of positive maternal urine toxicology screens at the time of delivery (35.9% vs 74.4%; P<.001). CONCLUSION: Among a cohort of rural pregnant women with opioid use disorder, receiving integrated obstetrical care and opioid use disorder treatment was associated with a reduced risk for preterm birth, a lower risk for positive maternal urine toxicology screen at the time of delivery, and shorter infant hospitalization. This relationship was mediated by the number of obstetrical visits attended during pregnancy, suggesting that increased engagement with obstetrical care through integration of services may contribute to improved perinatal outcomes.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Goodman DJ, Saunders EC, Frew JR, et al. Integrated vs nonintegrated treatment for perinatal opioid use disorder: retrospective cohort study. Am J Obstet Gynecol MFM. 2021. PMID: 34543754. doi:10.1016/j.ajogmf.2021.100489

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。